Literature DB >> 23920693

Analysis and evaluation of clinical pathways in china.

Wei Xu1, Zhiyong Wang, Yanxin Zhu, Cheng Wu, Weiwei Chen, Yibing Geng.   

Abstract

To analyze and evaluate the Standard Clinical Pathways (CPs) in China and suggest improvements for future revisions, we reviewed and evaluated the Standard CPs in China based on CP evaluation framework and the standard functions for eCP. We found that Standard CPs in China can basically meet the requirements of evaluation criteria and the standard function for eCPs, but still have problems in recording, editing and statistics. Standard CPs in China are still paper-based designs, and are not applicable for the computer and network environment. Further improvement should be done in the following directions including regulating and standardizing representations of items in the cells of CP checklists, modeling and templating CP checklists, and developing variance codes.

Mesh:

Year:  2013        PMID: 23920693

Source DB:  PubMed          Journal:  Stud Health Technol Inform        ISSN: 0926-9630


  1 in total

1.  China launched a pilot project to improve its rare disease healthcare levels.

Authors:  Yazhou Cui; Xiaoyan Zhou; Jinxiang Han
Journal:  Orphanet J Rare Dis       Date:  2014-01-27       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.